POMALYST® (pomalidomide) is a thalidomide analogue indicated, in combination with dexamethasone, for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
POMALYST Videos and Perspectives
Combination Regimens with POMALYST
26:49
Dr. Ken Shain provides his perspective on the use of combinations with POMALYST in the treatment of patients with RRMM who have progressed on REVLIMID.‡
Triplets with POMALYST
24:27
Dr. Jeffrey Matous shares his
insights about a triplet
combination with POMALYST.
Mechanism of Action
2:07
Explore the mechanism of action
of POMALYST.
‡Patients must have also received a PI.
Find More ResourcesPOMALYST + dex is a proven treatment option in REVLIMID-refractory patients who have also received a PI.1
In the POMALYST doublet Phase 3 trial, the majority of patients studied were refractory to REVLIMID.
REVLIMID
bortezomib
both
Triplets with POMALYST
DPd CLINICAL TRIAL
EFFICACY ENDPOINT
Overall response
rate.2
Learn about POMALYST + dex +
dara (DPd).
EMPLICITI® (elotuzumab)
CLINICAL TRIAL PRIMARY
ENDPOINT
Progression-free
survival.3
Learn about POMALYST + dex +
EMPLICITI.
IsaPd CLINICAL TRIAL
PRIMARY ENDPOINT
Progression-free
survival.4
Learn about POMALYST + dex +
isa (IsaPd).
Information about POMALYST + dex + daratumumab (dara) and POMALYST + dex + isatuximab (isa) does not appear in the POMALYST full Prescribing Information. Please see the dara and isa full Important Safety Information and full Prescribing Information at www.darzalex.com (dara) and www.sarclisa.com (isa). Please see full Prescribing Information for EMPLICITI (elotuzumab) in the tray below.

A single source for access support.
At Celgene Patient Support, we care about making sure your patients get the answers they need.

Customizable treatment calendar.
MM appointments and treatment schedules can get complicated. Help patients stay organized with this customizable calendar that you can email or print.
dara, daratumumab; isa, isatuximab-irfc; MM, multiple myeloma; PI, proteasome inhibitor; RRMM, relapsed/refractory multiple myeloma.
References: 1. POMALYST [package insert]. Summit, NJ: Celgene Corp. 2. Daratumumab [package insert]. Horsham, PA: Janssen Biotech, Inc. 3. EMPLICITI [package insert]. Princeton, NJ: Bristol-Myers Squibb Company. 4. Isatuximab-irfc [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC.